GoldenGolden
Advanced Search
Prevail Therapeutics

Prevail Therapeutics

Prevail Therapeutics is a New York City-based biotechnology company and a wholly owned subsidiary of Eli Lilly and Company.

Prevail Therapeutics is developing gene therapies intended to target the root genetic causes of Parkinson's disease and other neurodegenerative disorders. The company's goal is to develop these gene therapies through advances in human genetics and gene therapy technology.

Timeline

March 2019
Prevail Therapeutics raises a $50,000,000 series B round from AbbVie Inc., Adage Capital Management, Biotechnology Value Fund, Boxer Capital, EcoR1 Capital, Omega Funds, OrbiMed, Pontifax Venture Capital, RA Capital Management and Surveyor Capital.
March 8, 2018
Prevail Therapeutics raises a $75,000,000 series A round from Adage Capital Management, Alexandria Venture Investments, Biotechnology Value Fund, Boxer Capital, EcoR1 Capital, Omega Funds, OrbiMed, Pontifax Venture Capital and RA Capital Management.
August 1, 2017
Prevail Therapeutics raises a $4,000,000 seed round.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Phil Taylor
December 15, 2020
FierceBiotech
Eli Lilly has joined the ranks of big pharma companies building a position in gene therapy, paying $26.50 per share to take control of New York-based Prevail Therapeutics and its two clinical-stage development programs.
Eli Lilly and Company
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.